A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Morris, Michael J.
Wong, Jeffrey Y. C.
Nordquist, Luke
Szmulewitz, Russell Zelig
Agarwal, Neeraj
Attiyeh, Edward F.
Max, Steven I.
Divgi, Chaitanya R.
Patricia, Daniel
Cao, Yu
Li, Xiang
Yu, Alex
Urtishak, Karen
Lauring, Josh David
Sartor, Oliver
机构：
[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] XCanc Omaha, Omaha, NE USA
[4] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA
[5] Huntsman Canc Inst, Salt Lake City, UT USA
[6] Janssen Res & Dev LLC, Spring House, PA USA
[7] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5010
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer
    Morris, Michael J.
    Sartor, A. Oliver
    Wong, Jeffrey Y. C.
    Max, Steven I.
    Xie, Hong
    Yu, Alex
    Divgi, Chaitanya R.
    Patricia, Daniel
    Avadhani, Anjali Narayan
    Pandit-Taskar, Neeta
    Barata, Pedro C.
    Nordquist, Luke T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.
    Morris, Michael J.
    Sartor, A. Oliver
    Wong, Jeffrey Y. C.
    Max, Steven I.
    Xie, Hong
    Russell, Mike
    Divgi, Chaitanya R.
    Patricia, Daniel
    Avadhani, Anjali Narayan
    Nordquist, Luke T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)
    Zitzmann-Kolbe, Sabine
    Papple, Alex
    Poethko, Thorsten
    Moen, Ingrid
    Schatz, Christoph
    Hillier, Shawn
    Babich, John W.
    Cuthbertson, Alan
    Hagemann, Urs B.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer
    Pandit-Taskar, Neeta
    O'Donoghue, Joseph A.
    Chetty, Dushen
    Max, Steven
    Wanik, Danielle
    Ilovich, Ohad
    Russell, Michael
    Nyima, Tenzin
    Divgi, Chaitanya R.
    Yu, Margaret
    Morris, Michael J.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (07) : 1051 - 1056
  • [6] Radiation Dosimetry of Actinium (Ac-225) Rosopatamab Tetraxetan (Ac-RT): Anti-PSMA antibody labeled with an alpha emitter for targeted therapy of metastatic castration resistant prostate cancer (mCRPC)
    Vallabhajosula, Shankar
    He, Bin
    Tagawa, Scott
    Bander, Neil H.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [7] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Phase 0 study to assess [111In]-DOTA-h11B6 to target human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer
    Morris, Michael J.
    O'Donoghue, Joseph A.
    Chetty, Dushen
    Russell, Mike
    Zulch, Emma
    Avadhani, Anjali Narayan
    Divgi, Chaitanya R.
    Pandit-Taskar, Neeta
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [9] A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer
    Calvo, Emiliano
    Doger, Bernard
    Carles, Joan
    Peer, Avivit
    Sarid, David
    Eigl, Bernhard J.
    Avadhani, Anjali
    Yao, David
    Lin, Vincent
    Wu, Shujian
    Jaiprasart, Pharavee
    Loffredo, John
    Tamegnon, Monelle
    Xu, Weichun
    Xie, Hong
    Hansen, Aaron R.
    ONCOLOGIST, 2025, 30 (01):
  • [10] SatisfACtion: a phase 1/2 study of [225Ac]Ac-PSMA-R2 in patients with PSMA-positive metastatic castration-resistant prostate cancer with or without previous [177Lu]Lu-PSMA radioligand therapy
    Kraeber-Bodere, F.
    Mahammedi, H.
    Giraudet, A.
    Wehbe, J.
    Wilke, C.
    Olivier, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S280 - S280
12345